

9 November 2015

Dear Fellow Shareholders,

It gives me great pleasure to welcome you all here today at the first Annual General Meeting of Genetic Signatures as a publicly listed company.

It has been a milestone year in the Company's development after successful debut on the ASX on 31 March 2015, and a welcome result for shareholders who have seen the share price improve by approximately 30% from its initial public offering price of \$0.40. Our listing on the ASX marked another significant achievement for Genetic Signatures and was an important step in positioning the Company for its next stage of expansion into global markets. I give special thanks to our CEO Dr John Melki, the management team and all of our staff for their time and efforts in making this possible.

After many years in development I believe we are truly poised to become one of Australia's great biotech company success stories.

Over the past seven months the company has achieved a number of significant milestones including:

- Surpassing \$1m in annual revenue for the first time
- Growing product supply to major Australian hospital and pathology customers
- Achieved FDA listing for our patented *EasyScreen* kits
- Established European sales channels and partners
- Established US subsidiary and Business Development Team

Looking forward now, we are excited about what lies ahead. Global markets for Molecular Diagnostics are estimated at more than US\$1.1 billion and growing, with the US Centre for Disease Control and Prevention estimating there are over two million illnesses and 23,000 deaths alone in the US caused by infectious diseases. We aim to be a leading global supplier of diagnostic solutions to hospitals and pathology labs for rapid detection and treatment of infectious diseases and to that end we are about to commence the next exciting stage of company growth.

Commercialisation and growth plans are well underway in Europe and the US and I believe we are now on the doorstep of a significant growth period for the company as we target the very large US hospital market that is in need of the range of diagnostic products that Genetic Signatures offers – a high value, low cost solution to the growing problem of infectious disease danger.

Genetic Signatures expansion into the US is synchronistic with the implementation of the Preserve Access to Medicare Act which in effect will drive hospitals and pathology laboratories to the types of cost effective products that our Company offers, such as the *EasyScreen* range. With our new and highly credentialed US Business Development team in place, we are well poised to take significant advantage of the changing diagnostic and regulatory environment in the United States.

We are determined to take this Australian-developed technology to the world and we want our shareholders to join us on this journey. Through championing diagnostic change and progress, Genetic Signatures' future is going to be a very exciting one.

On behalf of the Board, Management and Genetic Signatures staff, I would like to thank our shareholders for their ongoing support.

Nick Samaris
Chairman

For further details:

Company

John Melki
Chief Executive Officer
john@geneticsignatures.com
T: +61 2 9870 7580

Media and Investor Relations

Peter Taylor
Investor Relations
peter@nwrcommunications.com.au
T: +61 412 036 231